Form D · Pharmaceuticals
MELINTA THERAPEUTICS, INC. /NEW/
New Haven, CT · CIK 0001461993
Offering snapshot reported Jan 19, 2018 · SEC filing
- Reported sold
- $138M Offering amount: $138M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 19, 2018 | Initial | $137,781,477 | No comparison | 9 | SEC filing |
| Nov 20, 2017 | Initial | $132,914,810 | No comparison | 39 | SEC filing |
| Oct 30, 2012 | Initial | $25,119,996 | No comparison | 13 | SEC filing |
| Aug 16, 2011 | Initial | $5,000,000 | No comparison | 16 | SEC filing |
| May 19, 2010 | Amendment | $45,999,999 | $20,500,000vs May 20, 2009 | 15 | SEC filing |
| May 20, 2009 | Initial | $25,499,999 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-303743
Amount sold includes shares given in consideration for an acquisition of stock of subsidiaries and assets of The Medicines Company.
Source: Form D, filed Jan 19, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shane Barton | Executive |
| Sue Cammarata | Executive |
| Michael L. Corrado | Director |
| Erin Duffy | Executive |
| Paul Estrem | Executive |
| Prabhavathi Fernandes | Director, Executive |
| Kevin T. Ferro | Director |
| Robin Gadsby | Director |
| Jay Galeota | Director |
| Jay J. Galeota, Jr. | Director |
| David Gill | Director |
| Dov Goldstein | Director |
| Cecilia Gonzalo | Director |
| Mark Hahn | Executive |
| John H. Johnson | Director |
| Richard Kent | Director |
| Thomas P. Koestler | Director |
| Garheng Kong | Director |
| I Wistar Morris | Director |
| P. Sherill Neff | Director |
| John Niedermayer | Executive |
| John Temperato | Executive |
| Geeta Vemuri | Director |
| Daniel Wechsler | Director, Executive |
| David Zaccardelli | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
300 George Street Suite 301
New Haven, CT, 06511
New Haven, CT, 06511